Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Rev. Saúde Pública Paraná (Online) ; 5(1): 2-18, Abr 1, 2022.
Artigo em Português | SESA-PR, CONASS | ID: biblio-1368450

RESUMO

O objetivo foi comparar o número de diagnóstico e óbito da hanseníase no Brasil no período de 2010 a 2020, considerando a pandemia de Covid-19, e assim analisar de que maneira este evento interferiu na sistemática de diagnóstico e óbito em pacientes com hanseníase. Estudo epidemiológico descritivo com abordagem quantitativa de dados secundários disponibilizados no DATASUS, que incluiu as informações de todas as notificações e óbitos entre indivíduos com hanseníase que tiveram no período citado, modo de entrada "caso novo", nos estados do Brasil. Os resultados mostraram tendência de queda anual no número total de novos casos de hanseníase no país, com grande redução em 2020. Em relação ao número de óbitos, a região Nordeste foi a responsável pela maior parte dos óbitos em pacientes em acompanhamento na última década. A pandemia intensifica desafios e vulnerabilidades anteriores, sendo imperativo implementar políticas públicas de saúde voltadas à hanseníase. (AU)


Objective of comparing the number of leprosy diagnosis and death in Brazil from 2010 to 2020, considering the Covid-19 pandemic, and thus to analyze how this event interfered in the systematic diagnosis and death in leprosy patients. Descriptive epidemiological study with quantitative approach of secondary data available in DATASUS, which included information on all notifications and deaths among individuals with leprosy who had thementioned period, mode of entry "new case", in the states of Brazil. The results showed an annual downward trend in the total number of new leprosy cases in the country, with a great reduction in the last evaluated year, 2020. In relation to the number ofdeaths, the Northeast region was responsible for most deaths in patients under follow-up in the last decade.The pandemic intensifies previous challenges and vulnerabilities, and it is imperative to implement public health policies focused on leprosy. (AU)


Assuntos
Humanos , Infecções por Coronavirus , Doenças Negligenciadas , Hanseníase
2.
Sci Rep ; 11(1): 23437, 2021 12 06.
Artigo em Inglês | MEDLINE | ID: mdl-34873205

RESUMO

Praziquantel is the only available drug to treat schistosomiasis, a parasitic disease that currently infects more than 240 million people globally. Due to increasing concerns about resistance and inadequate efficacy there is a need for new therapeutics. In this study, a series of 17 pyrazolines (15-31) and three pyrazoles (32-34) were synthesized and evaluated for their antiparasitic properties against ex vivo adult Schistosoma mansoni worms. Of the 20 compounds tested, six had a 50% effective concentration (EC50) below 30 µM. Our best hit, pyrazoline 22, showed promising activity against adult schistosomes, with an EC50 < 10 µM. Additionally, compound 22 had low cytotoxicity, with selectivity index of 21.6 and 32.2 for monkey and human cell lines, respectively. All active pyrazolines demonstrated a negative effect on schistosome fecundity, with a marked reduction in the number of eggs. Structure-activity relationship analysis showed that the presence of the non-aromatic heterocycle and N-substitution are fundamental to the antischistosomal properties. Pharmacokinetics, drug-likeness and medicinal chemistry friendliness studies were performed, and predicted values demonstrated an excellent drug-likeness profile for pyrazolines as well as an adherence to major pharmaceutical companies' filters. Collectively, this study demonstrates that pyrazoline derivatives are promising scaffolds in the discovery of novel antischistosomal agents.


Assuntos
Pirazóis/química , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose mansoni/tratamento farmacológico , Esquistossomose mansoni/parasitologia , Esquistossomicidas/farmacologia , Animais , Antiparasitários/farmacologia , Chalconas/química , Química Farmacêutica/métodos , Chlorocebus aethiops , Simulação por Computador , Descoberta de Drogas , Haplorrinos , Humanos , Camundongos , Praziquantel/farmacologia , Solventes , Relação Estrutura-Atividade , Sais de Tetrazólio/química , Tiazóis/química , Células Vero
3.
Acta Trop ; 205: 105350, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-31962096

RESUMO

Schistosomiasis is one of the most important parasitic infections in terms of its negative effects on public health and economics. Since praziquantel is currently the only drug available to treat schistosomiasis, there is an urgent need to identify new anthelmintic agents. Piplartine, also known as piperlongumine, is a biologically active alkaloid/amide from peppers that can be detected in high amounts in the roots of Piper tuberculatum. Previously, it has been shown to have in vitro schistosomicidal effects. However, its anthelmintic activity in an animal host has not been reported. In the present work, in vivo antischistosomal properties of isolated piplartine were evaluated in a mouse model of schistosomiasis infected with either adult (patent infection) or juvenile (pre-patent infection) stages of Schistosoma mansoni. A single dose of piplartine (100, 200 or 400 mg/kg) or daily doses for five consecutive days (100 mg/kg/day) administered orally to mice infected with schistosomes resulted in a reduction in worm burden and egg production. Treatment with the highest piplartine dose (400 mg/kg) caused a significant reduction in a total worm burden of 60.4% (P < 0.001) in mice harbouring adult parasites. S. mansoni egg production, a process responsible for pathology in schistosomiasis, was also significantly inhibited by piplartine. Studies using scanning electron microscopy revealed substantial tegumental alterations in parasites recovered from mice. Since piplartine has well-characterized mechanisms of toxicity, is easily available, and is cost-effective, our results indicate that this bioactive molecule derived from medicinal plants could be a potential lead compound for novel antischistosomal agents.


Assuntos
Piperidonas/uso terapêutico , Esquistossomose mansoni/tratamento farmacológico , Esquistossomicidas/uso terapêutico , Animais , Modelos Animais de Doenças , Feminino , Camundongos , Piper/química
4.
Antimicrob Agents Chemother ; 63(12)2019 09 09.
Artigo em Inglês | MEDLINE | ID: mdl-31527034

RESUMO

The treatment and control of schistosomiasis, a neglected disease that affects more than 200 million people worldwide, rely on the use of a single drug, praziquantel. A vaccine has yet to be developed and since new drug design and development is a lengthy and costly process, drug repurposing is a promising strategy. In this study, the efficacy of promethazine, a first-generation antihistamine, was evaluated against Schistosoma mansoni ex vivo and in a murine model of schistosomiasis. In vitro assays demonstrated that promethazine affected parasite motility, viability, and it induced severe tegumental damage in schistosomes. The LC50 of the drug was 5.84 µM. Similar to promethazine, schistosomes incubated with atropine, a classical anticholinergic drug, displayed reduced motor activity. In an animal model, promethazine treatment was introduced at an oral dose of 100 mg/kg for five successive days at different intervals from the time of infection, for the evaluation of the stage-specific susceptibility (pre-patent and patent infections). Various parasitological criteria indicated the in vivo antischistosomal effects of promethazine: there were significant reductions in worm burden, egg production, and hepato- and splenomegaly. The highest worm burden reduction was achieved with promethazine in patent infections (> 90%). Taken together, considering the importance of the repositioning of drugs in infectious diseases, especially those related to poverty, our data revealed the possibility of promethazine repositioning as an antischistosomal agent.

5.
Acta Trop ; 123(1): 53-7, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22476130

RESUMO

Recent evidences have demonstrated the importance of Th17 cells in host defense against infectious diseases. However, little is known about their role in parasitic infections. Here, we showed that uncomplicated acute vivax malaria induce a significant expansion of IL-17-producing CD4(+) T cells associated to a pro-inflammatory cytokine profile. Furthermore, we demonstrated a correlation between numbers of IL-17(+)CD4(+) T cells and circulating CD4(+) T-cells producing IFN-γ, IL-10 and TGF-ß. Finally, correlations between number of these cells and morbidity or parasitemia were not detected. Further studies are underway to investigate whether IL-17-producing CD4(+) T cells are critically involved in the immunity against Plasmodium vivax infection.


Assuntos
Interleucina-17/metabolismo , Malária Vivax/imunologia , Plasmodium vivax/imunologia , Células Th17/imunologia , Adulto , Linfócitos T CD4-Positivos/imunologia , Humanos , Interferon gama/metabolismo , Interleucina-10/metabolismo , Pessoa de Meia-Idade , Subpopulações de Linfócitos T/imunologia , Fator de Crescimento Transformador beta/metabolismo
6.
Microbes Infect ; 14(9): 730-9, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22445906

RESUMO

An important step when designing a vaccine is identifying the antigens that function as targets of naturally acquired antibodies. We investigated specific antibody responses against two Plasmodium vivax vaccine candidates, PvMSP-119 and PvMSP-3α359₋798. Moreover, we assessed the relationship between these antibodies and morbidity parameters. PvMSP-119 was the most immunogenic antigen and the frequency of responders to this protein tended to increase in P. vivax patients with higher parasitemia. For both antigens, IgG antibody responses tended to be lower in patients who had experienced their first bout of malaria. Furthermore, anemic patients presented higher IgG antibody responses to PvMSP-3α359₋798. Since the humoral response involves a number of antibodies acting simultaneously on different targets, we performed a Principal Component Analysis (PCA). Anemic patients had, on average, higher first principal component scores (IgG1/IgG2/IgG3/IgG4 anti-MSP3α), which were negatively correlated with hemoglobin levels. Since antibodies against PfMSP-3 have been strongly associated with clinical protection, we cannot exclude the possibility of a dual role of PvMSP-3 specific antibodies in both immunity and pathogenesis of vivax malaria. Our results confirm the high immunogenicity of the conserved C terminus of PvMSP-1 and points to the considerable immunogenicity of polymorphic PvMSP-3α359₋798 during natural infection.


Assuntos
Anticorpos Antiprotozoários/sangue , Antígenos de Protozoários/imunologia , Vacinas Antimaláricas/imunologia , Malária Vivax/imunologia , Proteína 1 de Superfície de Merozoito/imunologia , Plasmodium vivax/imunologia , Proteínas de Protozoários/imunologia , Adolescente , Adulto , Idoso , Brasil , Criança , Feminino , Humanos , Imunoglobulina G/sangue , Vacinas Antimaláricas/administração & dosagem , Masculino , Pessoa de Meia-Idade , Adulto Jovem
7.
PLoS One ; 6(6): e21289, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21713006

RESUMO

Apical membrane antigen 1 (AMA-1) is considered to be a major candidate antigen for a malaria vaccine. Previous immunoepidemiological studies of naturally acquired immunity to Plasmodium vivax AMA-1 (PvAMA-1) have shown a higher prevalence of specific antibodies to domain II (DII) of AMA-1. In the present study, we confirmed that specific antibody responses from naturally infected individuals were highly reactive to both full-length AMA-1 and DII. Also, we demonstrated a strong association between AMA-1 and DII IgG and IgG subclass responses. We analyzed the primary sequence of PvAMA-1 for B cell linear epitopes co-occurring with intrinsically unstructured/disordered regions (IURs). The B cell epitope comprising the amino acid sequence 290-307 of PvAMA-1 (SASDQPTQYEEEMTDYQK), with the highest prediction scores, was identified in domain II and further selected for chemical synthesis and immunological testing. The antigenicity of the synthetic peptide was identified by serological analysis using sera from P. vivax-infected individuals who were knowingly reactive to the PvAMA-1 ectodomain only, domain II only, or reactive to both antigens. Although the synthetic peptide was recognized by all serum samples specific to domain II, serum with reactivity only to the full-length protein presented 58.3% positivity. Moreover, IgG reactivity against PvAMA-1 and domain II after depletion of specific synthetic peptide antibodies was reduced by 18% and 33% (P = 0.0001 for both), respectively. These results suggest that the linear epitope SASDQPTQYEEEMTDYQK is highly antigenic during natural human infections and is an important antigenic region of the domain II of PvAMA-1, suggesting its possible future use in pre-clinical studies.


Assuntos
Antígenos de Protozoários/imunologia , Epitopos de Linfócito B/imunologia , Proteínas de Membrana/imunologia , Plasmodium vivax/imunologia , Proteínas de Protozoários/imunologia , Adolescente , Adulto , Idoso , Sequência de Aminoácidos , Animais , Anticorpos Antiprotozoários/sangue , Anticorpos Antiprotozoários/genética , Anticorpos Antiprotozoários/imunologia , Antígenos de Protozoários/genética , Humanos , Malária Vivax/sangue , Malária Vivax/imunologia , Malária Vivax/microbiologia , Proteínas de Membrana/genética , Pessoa de Meia-Idade , Dados de Sequência Molecular , Peptídeos/genética , Peptídeos/imunologia , Plasmodium vivax/citologia , Proteínas de Protozoários/genética , Adulto Jovem
8.
Malar J ; 9: 229, 2010 Aug 09.
Artigo em Inglês | MEDLINE | ID: mdl-20696056

RESUMO

BACKGROUND: Humoral immune responses play a key role in the development of immunity to malaria, but the host genetic factors that contribute to the naturally occurring immune responses to malarial antigens are not completely understood. The aim of the present investigation was to determine whether, in subjects exposed to malaria, GM and KM allotypes--genetic markers of immunoglobulin gamma and kappa-type light chains, respectively--contribute to the magnitude of natural antibody responses to target antigens that are leading vaccine candidates for protection against Plasmodium vivax. METHODS: Sera from 210 adults, who had been exposed to malaria transmission in the Brazilian Amazon endemic area, were allotyped for several GM and KM determinants by a standard hemagglutination-inhibition method. IgG subclass antibodies to P. vivax apical membrane antigen 1 (PvAMA-1) and merozoite surface protein 1 (PvMSP1-19) were determined by an enzyme-linked immunosorbent assay. Multiple linear regression models and the non-parametric Mann-Whitney test were used for data analyses. RESULTS: IgG1 antibody levels to both PvMSP1-19 and PvAMA-1 antigens were significantly higher (P = 0.004, P = 0.002, respectively) in subjects with the GM 3 23 5,13,14 phenotype than in those who lacked this phenotype. CONCLUSIONS: Results presented here show that immunoglobulin GM allotypes contribute to the natural antibody responses to P. vivax malaria antigens. These findings have important implications for the effectiveness of vaccines containing PvAMA-1 or PvMSP1-19 antigens. They also shed light on the possible role of malaria as one of the evolutionary selective forces that may have contributed to the maintenance of the extensive polymorphism at the GM loci.


Assuntos
Anticorpos Antiprotozoários/imunologia , Antígenos de Protozoários/imunologia , Imunoglobulina G/imunologia , Malária Vivax/imunologia , Plasmodium vivax/imunologia , Adulto , Anticorpos Antiprotozoários/sangue , Antígenos de Protozoários/genética , Brasil , Ensaio de Imunoadsorção Enzimática , Feminino , Marcadores Genéticos , Humanos , Imunoglobulina G/sangue , Alótipos Gm de Imunoglobulina/genética , Alótipos Gm de Imunoglobulina/imunologia , Alótipos Km de Imunoglobulina/genética , Alótipos Km de Imunoglobulina/imunologia , Modelos Lineares , Vacinas Antimaláricas/imunologia , Malária Vivax/prevenção & controle , Masculino , Proteínas de Membrana/imunologia , Proteína 1 de Superfície de Merozoito/imunologia , Pessoa de Meia-Idade , Fenótipo , Plasmodium vivax/genética , Proteínas de Protozoários/imunologia , Estatísticas não Paramétricas , Adulto Jovem
9.
PLoS One ; 5(3): e9623, 2010 Mar 10.
Artigo em Inglês | MEDLINE | ID: mdl-20224778

RESUMO

Circulation CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) have been associated with the delicate balancing between control of overwhelming acute malaria infection and prevention of immune pathology due to disproportionate inflammatory responses to erythrocytic stage of the parasite. While the role of Tregs has been well-documented in murine models and P. falciparum infection, the phenotype and function of Tregs in P. vivax infection is still poorly characterized. In the current study, we demonstrated that patients with acute P. vivax infection presented a significant augmentation of circulating Tregs producing anti-inflammatory (IL-10 and TGF-beta) as well as pro-inflammatory (IFN-gamma, IL-17) cytokines, which was further positively correlated with parasite burden. Surface expression of GITR molecule and intracellular expression of CTLA-4 were significantly upregulated in Tregs from infected donors, presenting also a positive association between either absolute numbers of CD4(+)CD25(+)FoxP3(+)GITR(+) or CD4(+)CD25(+)FoxP3(+)CTLA-4(+) and parasite load. Finally, we demonstrate a suppressive effect of Treg cells in specific T cell proliferative responses of P. vivax infected subjects after antigen stimulation with Pv-AMA-1. Our findings indicate that malaria vivax infection lead to an increased number of activated Treg cells that are highly associated with parasite load, which probably exert an important contribution to the modulation of immune responses during P. vivax infection.


Assuntos
Linfócitos T CD4-Positivos/citologia , Fatores de Transcrição Forkhead/biossíntese , Subunidade alfa de Receptor de Interleucina-2/biossíntese , Malária/parasitologia , Plasmodium vivax/genética , Adulto , Antígenos CD/metabolismo , Antígeno CTLA-4 , Proliferação de Células , Humanos , Interferon gama/metabolismo , Interleucina-10/metabolismo , Interleucina-17/metabolismo , Malária/sangue , Pessoa de Meia-Idade , Fenótipo , Fator de Crescimento Transformador beta/metabolismo
10.
Vaccine ; 27(41): 5581-8, 2009 Sep 18.
Artigo em Inglês | MEDLINE | ID: mdl-19651176

RESUMO

The Apical Membrane Antigen-1 (AMA-1) is a well-characterized and functionally important merozoite protein and is currently considered a major candidate antigen for a malaria vaccine. Previously, we showed that AMA-1 has an influence on cellular immune responses of malaria-naïve subjects, resulting in an alternative activation of monocyte-derived dendritic cells and induction of a pro-inflammatory response by stimulated PBMCs. Although there is evidence, from human and animal malaria model systems that cell-mediated immunity may contribute to both protection and pathogenesis, the knowledge on cellular immune responses in vivax malaria and the factors that may regulate this immunity are poorly understood. In the current work, we describe the maturation of monocyte-derived dendritic cells of P. vivax naturally infected individuals and the effect of P. vivax vaccine candidate Pv-AMA-1 on the immune responses of the same donors. We show that malaria-infected subjects present modulation of DC maturation, demonstrated by a significant decrease in expression of antigen-presenting molecules (CD1a, HLA-ABC and HLA-DR), accessory molecules (CD40, CD80 and CD86) and FcgammaRI (CD64) receptor (P < or = 0.05). Furthermore, Pv-AMA-1 elicits an upregulation of CD1a and HLA-DR molecules on the surface of monocyte-derived dendritic cells (P=0.0356 and P=0.0196, respectively), and it is presented by AMA-1-stimulated DCs. A significant pro-inflammatory response elicited by Pv-AMA-1-pulsed PBMCs is also demonstrated, as determined by significant production of TNF-alpha, IL-12p40 and IFN-gamma (P < or = 0.05). Our results suggest that Pv-AMA-1 may partially revert DC down-modulation observed in infected subjects, and exert an important role in the initiation of pro-inflammatory immunity that might contribute substantially to protection.


Assuntos
Antígenos de Protozoários/imunologia , Células Dendríticas/imunologia , Malária Vivax/imunologia , Proteínas de Membrana/imunologia , Plasmodium vivax/imunologia , Proteínas de Protozoários/imunologia , Animais , Antígenos CD/biossíntese , Células Cultivadas , Citocinas/metabolismo , Regulação para Baixo , Antígenos HLA/biossíntese , Humanos , Regulação para Cima
11.
Am J Trop Med Hyg ; 75(4): 582-7, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17038677

RESUMO

The antibody responses to the apical membrane antigen 1 of the Plasmodium vivax (PvAMA-1) were investigated in subjects living in areas of Brazil with different levels of malaria transmission. The prevalence and the levels of IgG to PvAMA-1 increased with the time of exposure. The frequency of a positive response and the mean IgG level were higher in areas where malaria prevalence was more intense, especially among non-infected subjects exposed to moderate transmission over a period of 20 years. The proportions and levels of IgG1and IgG3 isotypes were significantly higher among those subjects with long-term exposure. Antibodies, mainly IgG1, to PvAMA-1 persisted for seven years among subjects briefly exposed to malaria in an outbreak outside the Brazilian malaria-endemic area. These data show the highly immunogenic properties of PvAMA-1 and emphasize its possible use as a malaria vaccine candidate.


Assuntos
Anticorpos Antiprotozoários/sangue , Antígenos de Protozoários/imunologia , Doenças Endêmicas , Malária Vivax/transmissão , Proteínas de Membrana/imunologia , Plasmodium vivax/imunologia , Proteínas de Protozoários/imunologia , Adulto , Animais , Brasil/epidemiologia , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Imunoglobulina G/sangue , Imunoglobulina G/classificação , Malária Vivax/epidemiologia , Malária Vivax/imunologia , Masculino , Fatores de Tempo
12.
Rev. bras. ter. intensiva ; 18(3): 229-233, jul.-set. 2006. tab
Artigo em Português | LILACS | ID: lil-481511

RESUMO

JUSTIFICATIVA E OBJETIVOS: O sangramento digestivo por úlcera de estresse (SDUE) é uma complicação grave dos pacientes criticamente doentes e com necessidade de profilaxia baseada em critérios literários definidos. O objetivo deste estudo foi revisar o uso de profilaxia para SDUE em UTI do Estado do Rio Grande do Sul, comparando os resultados com as evidências atuais da literatura. MÉTODO: Estudo transversal realizado em um único dia, com coleta de dados de todos os pacientes internados em 21 unidades de terapia intensiva (UTI). Para análise dos dados, os pacientes foram distribuídos em três subgrupos (alto, médio e baixo risco de SDUE). RESULTADOS: Foram analisados 235 pacientes internados, com média de idade de 57,7 ± 19,5 anos e tempo médio de internação em UTI de 13 ± 19,7 dias. Os motivos de internação mais freqüentes foram sepse (26 por cento) e pós-operatório de grandes cirurgias (16,2 por cento). Da totalidade, 73 por cento eram de alto risco para SDUE, 21,5 por cento de risco intermediário e 5,5 por cento de baixo risco. Dos 187 pacientes de alto risco, 139 estavam usando bloqueadores para SDUE (60 por cento com bloqueadores histaminérgicos (BH2) e 39 por cento com inibidor de bomba de prótons (IBP) para profilaxia (60 por cento). Não recebiam profilaxia, apesar de indicada, 25,7 por cento destes pacientes de alto risco. Dos 55 pacientes de risco intermediário para SDUE, 70,9 por cento recebiam profilaxia (22 com BH2 e 17 com IBP) e dos 14 pacientes de baixo risco, 71 por cento recebiam profilaxia (6 com BH2 e 4 com IBP). CONCLUSÕES: Este artigo traduziu a ausência de estratificação de risco para SDUE nas UTI do Estado, além da indicação de fármacos gastro-protetores sem critérios precisos para o seu emprego.


BACKGROUND AND OBJECTIVES: Gastrointestinal bleeding due to stress ulcer (GB) complicates critical disease, and must be received prophylaxis based on defined criteria. To evaluate the GB prophylaxis in Intensive Care Units (ICU), and to compare with the guidelines. METHODS: We carried out a cross-sectional multicenter study in 21 medical-surgical ICU in Brazil to investigate this issue. For data analysis, these were distributed in 3 sub-groups (high, moderate and low risk for GB). RESULTS: 235 patients were evaluated, with mean age of 57.7 ± 19.5 years and days on ICU 13 ± 19.7. The more common admission ICU diagnoses were sepsis (26 percent) and postoperative (16.2 percent) patients. Seventy-three (73 percent) of the patients were GB high risk, 21.5 percent moderate and 5.5 percent low risk. Of the 187 high risk patients, 139 were receiving GB prophylaxis (60 percent with histamine blockers (HB2) and 39 percent with proton pump inhibitors (PPI). Of these patients, 25.7 percent did not receive GU prophylaxis, although indicated it. Of the 55 moderate risk patients, 70.9 percent wer e receiving GU prophylaxis (22 with HB2 and 17 with PPI). Of the 14 low risk patients, 71 percent were using GU prophylaxis (6 with HB2 and 4 with PPI). CONCLUSIONS: Almost 80 percent of the patients made use of GB prophylactic drugs, with no agreement GU risk stratification. This study demonstrated the no adequate GU prophylaxis in the Brazilian ICU.


Assuntos
Unidades de Terapia Intensiva , Úlcera Péptica , Úlcera/prevenção & controle , Estresse Fisiológico
13.
Parasitol Res ; 95(6): 420-6, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15759156

RESUMO

Subclasses of antibodies to the C-terminal 19 kDa fragment of the Plasmodium vivax merozoite surface protein 1 (PvMSP-1(19)) were assessed among subjects with distinct degrees of malaria exposure in the Brazilian endemic area. The PvMSP-1(19) specific IgG1and IgG3 levels were low among subjects with long-term exposure (approximately 19 years) when compared to subjects less and sporadically exposed (<1 year). No statistically difference was observed in IgG subclass distribution of antibodies from symptomatic Plasmodium-infected patients, asymptomatic parasite carriers and non-infected subjects living in a same mesoendemic area. Subjects briefly exposed to a P. vivax outbreak living in a rural community outside the endemic area were also evaluated to measure the persistence of specific antibodies. IgG anti-PvMSP-1(19) antibodies persisted in 40% of the subjects who had had malarial symptoms 8 months before and decreased after 7 years (28%). Specific IgG1 were the predominant isotype. Our study emphasizes the highly immunogenicity of the PvMSP-1(19) and points toward its possible use as a potential malaria vaccine.


Assuntos
Surtos de Doenças , Doenças Endêmicas , Isotipos de Imunoglobulinas/sangue , Proteína 1 de Superfície de Merozoito/imunologia , Plasmodium vivax/imunologia , Adulto , Animais , Anticorpos Antiprotozoários/sangue , Brasil/epidemiologia , Feminino , Humanos , Imunoglobulina G/sangue , Malária Falciparum/epidemiologia , Malária Falciparum/imunologia , Masculino , Proteína 1 de Superfície de Merozoito/genética
14.
Am J Trop Med Hyg ; 66(5): 461-6, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-12201577

RESUMO

The antibody response to the C-terminal 19-kD fragment of Plasmodium falciparum merozoite surface protein-1 (PfMSP1-19) was investigated in groups of subjects living in areas of Brazil with different levels of malaria transmission. The prevalence and the levels of IgG to PfMSP1-19 increased with the time of exposure and were positively correlated with the absence of clinical symptoms in parasitemic patients. The frequency of positive response and the mean level of IgG were higher in areas where malaria prevalence was more intense, especially among asymptomatic patients. The serum absorbance values of the IgG1 isotype were significantly higher among subjects with long-term exposure and in asymptomatic infections. These data suggest a protective role of IgG1 in naturally acquired immunity in spite of the unstable transmission levels in the Brazilian Amazon.


Assuntos
Anticorpos Antiprotozoários/sangue , Imunidade Inata/imunologia , Imunoglobulina G/imunologia , Malária Falciparum/imunologia , Proteína 1 de Superfície de Merozoito/imunologia , Plasmodium falciparum/imunologia , Adulto , Animais , Formação de Anticorpos , Brasil , Feminino , Humanos , Isotipos de Imunoglobulinas/sangue , Masculino , Plasmodium vivax/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA